DENVER, May 6, 2020 /PRNewswire/ — BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, today announced the advancement of its medical-grade biosensor product portfolio and Data-as-a-Service (DaaS) platform with the introduction of the BioButton™ device. The BioButton is a coin-sized, disposable medical device that measures continuous temperature and other vital signs for a remarkable 90-days. BioIntelliSense offers medical-grade data services that allow for early detection of adverse trends through its proprietary biosensor technology and advanced analytics at a fraction of the cost of spot temperature measurements or traditional Remote Patient Monitoring (RPM) systems.
BioIntelliSense’s BioButton medical-grade device and HIPAA-compliant data services enable effortless remote data capture and continuous multi-parameter monitoring of temperature, respiratory rate and heart rate at rest, body position, sleep and activity state for 90-days on a single disposable on-body sensor.
“The introduction of the BioButton device, in combination with the BioMobile applications and enterprise triage dashboards, represents a significant advancement in making continuous medical-grade monitoring reliable, effortless and cost-effective,” said James Mault, MD, CEO of BioIntelliSense. “The convenience of the BioButton will support a range of clinical use cases for RPM reimbursement and mass market use to enable safe return to work or school.”
The BioIntelliSense DaaS platform can be successfully applied to a wide range of COVID-19 related use cases for the monitoring of returning workforce and students, high-risk patient populations, patients in-hospital and in-home along with frontline healthcare professionals.
To learn more about the the BioIntelliSense BioButton for remote monitoring and early detection of COVID-19 visit www.biointellisense.com
About BioIntelliSense
BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience. The FDA-cleared BioSticker™ and BioButton™ devices make remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians will now have access to high-resolution patient trending and reporting to enable medical grade care at home.
For more information on how BioIntelliSense is redefining remote patient monitoring through medical-grade and cost-effective data services, please contact us at info@biointellisense.com or visit our website at BioIntelliSense.com.
Media Contact:
BioIntelliSense, Inc.
Carolyn Walsh
Chief Commercial Officer
cwalsh@BioIntelliSense.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/biointellisense-introduces-the-biobutton-for-90-days-of-continuous-wireless-temperature-and-vital-signs-monitoring-on-a-coin-sized-disposable-medical-device-301053694.html
SOURCE BioIntelliSense, Inc.
NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Report with market evolution powered by AI -…
KING OF PRUSSIA, Pa., Jan. 22, 2025 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS)…
NORTON, Va., LA ROCHELLE, France and BUDAPEST, Hungary, Jan. 22, 2025 /PRNewswire/ -- Today, SOLARBIOTECH, GPC Bio,…
DOWNERS GROVE, Ill., Jan. 22, 2025 /PRNewswire/ -- Systech, part of Markem-Imaje and Dover and…
TROY, Mich., Jan. 22, 2025 /PRNewswire/ -- Altair Engineering Inc. ("Altair") (Nasdaq: ALTR), a global leader…
Lori Logan named as successor ATLANTA, Jan. 22, 2025 /PRNewswire/ -- John Ladaga announced today that…